Jean-Yves Nothias
Gründer bei Vesale Partners SAS
Profil
Mr. Jean-Yves Nothias leads the Biotechnology Team at SGAM Alternative Investments.
He oversees all portfolio companies and has made significant contributions by bringing in CEOs, syndicating financial rounds and providing strategic advice.
Previously, he was a biotechnology analyst for Hambrecht & Quist based in Paris.
He worked at F.
Hoffmann-La Roche (US) and several scientific institutions in France and in the US.
Mr. Nothias holds a PhD in molecular biology from Université Paris VI and a masters degree in management from Université Paris Sorbonne.
Aktive Positionen von Jean-Yves Nothias
| Unternehmen | Position | Beginn |
|---|---|---|
Vesalius Biocapital Partners SARL
 Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Private Equity Investor | 01.12.2011 |
| Vesale Partners SAS | Gründer | 01.01.2012 |
| FCPR Biotechnology Fund | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Jean-Yves Nothias
| Unternehmen | Position | Ende |
|---|---|---|
| GENOMIC VISION | Direktor/Vorstandsmitglied | 24.07.2016 |
| SCYNEXIS, INC. | Direktor/Vorstandsmitglied | 04.06.2015 |
Amundi Private Equity Funds SA
 Amundi Private Equity Funds SA Investment ManagersFinance Amundi Private Equity Funds SA (Amundi PEF) is the private equity subsidiary of Amundi SA, itself a subsidiary of Crédit Agricole SA (XP: ACA) in France. Formerly known as CAAM-CI, founded in 1999 as CPR Private Equity, Amundi PEF was formed in 2009 by combining the Crédit Agricole and Société Générale asset management operations. The firm is headquartered in Paris and has additional offices in Bucharest, Cairo, Casablanca, Tunis and Warsaw. They invest in companies at all stages of development, providing institutional and individual investors with a wide spectrum of investment opportunities. | Director of Investments | 01.08.2011 |
Société Générale Asset Mgmt Alternative Invt (Private Equity)
 Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance Societé Générale Asset Management Alternative Investment/Private Equity (SGAM AI/PE) is the banking group's European asset management center for Private Equity. They are located in Paris-La Défense. SGAM AI/PE is a division of the Société Générale Asset Management, established in 2003, which is a subsidiary of the bank's Global Investment Management and Services division. The ultimate parent firm is the French financial institution Société Générale (PK: SCGLY), established in 1864. Nationalized at different intervals throughout their history, the bank is in the private sector since 1997. SGAM AI/PE is composed of three units: venture capital, expansion capital and buyout, and fund of funds. In addition to their Paris office, they are also present in London, Milan, Munich, Warsaw, Bucharest and Casablanca. | Head-Equity Investments | 07.04.2009 |
Gene-IT, Inc.
 Gene-IT, Inc. Packaged SoftwareTechnology Services Gene-IT, Inc. (GenomeQuest, Inc.) provides software solutions to life-science research organizations. It makes sequence information available to all end-users in life sciences. The firm identifies new applications and adapts sequence search technology to serve life science end-users. The company was founded by Dr. Jean-Jacques Codani and Eric Glémet in 1998 and is located in Westborough, MA. | Direktor/Vorstandsmitglied | 25.09.2007 |
Ausbildung von Jean-Yves Nothias
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SCYNEXIS, INC. | Health Technology |
| GENOMIC VISION | Health Technology |
| Private Unternehmen | 14 |
|---|---|
Gene-IT, Inc.
Gene-IT, Inc. Packaged SoftwareTechnology Services Gene-IT, Inc. (GenomeQuest, Inc.) provides software solutions to life-science research organizations. It makes sequence information available to all end-users in life sciences. The firm identifies new applications and adapts sequence search technology to serve life science end-users. The company was founded by Dr. Jean-Jacques Codani and Eric Glémet in 1998 and is located in Westborough, MA. | Technology Services |
GQ Life Sciences, Inc.
 GQ Life Sciences, Inc. Packaged SoftwareTechnology Services GQ Life Sciences, Inc. provides software solutions to life science research organizations. It offers LifeQuest, a patent search platform specific for the life sciences that provides a solution for semantic keyword and life science ontology searching; and GenomeQuest that integrates full-text search and sequence search in the intellectual property domain. The company was founded by Eric Glemet in 1998 and is headquartered in Boston, MA. | Technology Services |
| Université de Paris IV Paris-Sorbonne | Consumer Services |
| Université Pierre et Marie Curie | Consumer Services |
Picometrics SA
 Picometrics SA Electronic Equipment/InstrumentsElectronic Technology Picometrics SA manufactures Laser Induced Fluorescence (LIF) detectors for liquid separation analysis. Its products include ZETALIF Evolution, ZETALIF LED, and ZETALIF Discovery. The company's detectors have been used in the analysis of a range of molecules such as proteins, carbohydrates, alcohols, thiols, amines, aldehydes and ketones, organic acids, nucleotides as well as fluorescent pharmaceutical products and illicit drugs. The company was founded in 1998 and is headquartered in Toulouse, France. | Electronic Technology |
Trod Medical NV
 Trod Medical NV Medical SpecialtiesHealth Technology Trod Medical NV develops and commercializes tools for use in the focal ablation of soft tissues. The company was founded by Andre Scattolin Faure on June 29, 2006 and is headquartered in Leuven, Belgium. | Health Technology |
Société Générale Asset Mgmt Alternative Invt (Private Equity)
Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance Societé Générale Asset Management Alternative Investment/Private Equity (SGAM AI/PE) is the banking group's European asset management center for Private Equity. They are located in Paris-La Défense. SGAM AI/PE is a division of the Société Générale Asset Management, established in 2003, which is a subsidiary of the bank's Global Investment Management and Services division. The ultimate parent firm is the French financial institution Société Générale (PK: SCGLY), established in 1864. Nationalized at different intervals throughout their history, the bank is in the private sector since 1997. SGAM AI/PE is composed of three units: venture capital, expansion capital and buyout, and fund of funds. In addition to their Paris office, they are also present in London, Milan, Munich, Warsaw, Bucharest and Casablanca. | Finance |
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
Vesalius Biocapital Partners SARL
Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners SARL (Vesalius Biocapital Partners) is an independent venture capital firm founded in 2007 by Stéphane Verdood. The firm is headquartered in Luxembourg. | Finance |
BioSystems International SAS
 BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |
InGen Biosciences SA
 InGen Biosciences SA Medical SpecialtiesHealth Technology InGen Biosciences SA is engaged in the development of in-vitro diagnostic products for use in medical biology laboratories. The company was founded in 1993 and it is headquartered in Chilly-Mazarin, France. | Health Technology |
Amundi Private Equity Funds SA
Amundi Private Equity Funds SA Investment ManagersFinance Amundi Private Equity Funds SA (Amundi PEF) is the private equity subsidiary of Amundi SA, itself a subsidiary of Crédit Agricole SA (XP: ACA) in France. Formerly known as CAAM-CI, founded in 1999 as CPR Private Equity, Amundi PEF was formed in 2009 by combining the Crédit Agricole and Société Générale asset management operations. The firm is headquartered in Paris and has additional offices in Bucharest, Cairo, Casablanca, Tunis and Warsaw. They invest in companies at all stages of development, providing institutional and individual investors with a wide spectrum of investment opportunities. | Finance |
| FCPR Biotechnology Fund | |
| Vesale Partners SAS |
